Unknown

Dataset Information

0

Use and effectiveness of a fixed-ratio combination of insulin degludec/liraglutide (IDegLira) in a real-world population with type 2 diabetes: Results from a European, multicentre, retrospective chart review study.


ABSTRACT: AIMS:To describe the real-world use and effectiveness of IDegLira, a fixed-ratio combination of the basal insulin degludec, and the glucagon-like peptide-1 receptor agonist (GLP-1RA) liraglutide. MATERIALS AND METHODS:This European, multicentre, retrospective chart review comprised adults (n?=?611) with type 2 diabetes, who started IDegLira ?6?months before data collection. Clinical characteristics were assessed at baseline (defined as the most recent recording during the 6?months before the first IDegLira prescription) and 3, 6, 9 and 12?months (± 45?days for each time point) after commencing IDegLira, where data were available. RESULTS:Baseline regimens included non-injectable medications (19%), basal insulin (19%), GLP-1RA (10%), free combination therapy (insulin/GLP-1RA, 24%) and multiple daily-dose insulin injections (MDI, 28%), all?±?oral antidiabetic drugs. After 6 months, significant glycated haemoglobin (HbA1c) reductions were observed in patients overall and in all subgroups (-10 mmol/mol [-0.9%] overall; P?

SUBMITTER: Price H 

PROVIDER: S-EPMC5873250 | biostudies-literature | 2018 Apr

REPOSITORIES: biostudies-literature

altmetric image

Publications

Use and effectiveness of a fixed-ratio combination of insulin degludec/liraglutide (IDegLira) in a real-world population with type 2 diabetes: Results from a European, multicentre, retrospective chart review study.

Price Hermione H   Blüher Matthias M   Prager Rudolf R   Phan Tra-Mi TM   Thorsted Brian L BL   Schultes Bernd B  

Diabetes, obesity & metabolism 20180111 4


<h4>Aims</h4>To describe the real-world use and effectiveness of IDegLira, a fixed-ratio combination of the basal insulin degludec, and the glucagon-like peptide-1 receptor agonist (GLP-1RA) liraglutide.<h4>Materials and methods</h4>This European, multicentre, retrospective chart review comprised adults (n = 611) with type 2 diabetes, who started IDegLira ≥6 months before data collection. Clinical characteristics were assessed at baseline (defined as the most recent recording during the 6 months  ...[more]

Similar Datasets

| S-EPMC6594226 | biostudies-literature
| S-EPMC6593827 | biostudies-literature
| S-EPMC10439551 | biostudies-literature
| S-EPMC5399738 | biostudies-literature
| S-EPMC5399738 | biostudies-literature
| S-EPMC6899795 | biostudies-literature
| S-EPMC5343072 | biostudies-literature
| S-EPMC4894076 | biostudies-literature
| S-EPMC6900157 | biostudies-literature
| S-EPMC7843811 | biostudies-literature